Acorda Therapeutics, Inc. (ACOR)

poor management, this one's going no where.

Specializing in Neurological function repair and improvement. They have a drug that helps MS patients walk that should get FDA approval in January. I can sense that they are on the brink of other break throughs. Should get a boost when health care reform finally passes.

Nice pop to short...

Outperform

Negative Earnings Surprise

Overvalued. If you want in on the future of CNS research and production invest in a broader, safer buy like STEM. They will benefit from the production and storage regardless of who comes up with the new tech. Short the fall. Not sure when or if I would buy back in.

FDA approval seems likely.

I remember when I first purchase this stock at $ 6 something a share and drop to $ 1. it was very downgrade, I thought I made a mistake. So a year later $ 175000 was sitting on my back pocket, that's worth the price. From $ 1 to almost $ 36 a share, that's called trading, with no experience. It's worth the try...

I'm green thumbing Acorda as one of those win-win situations where I don't know the bottom. Fampridine obviously has too much behind it to be summarily dismissed by the FDA, so I'm counting on the rejection of the NDA submission to be a simple technical issue with minimal long-term implications. Once this issue is resolved, the share price will likely surpass recent highs. The period of quiescence before resolution may lead to further lows and a temporarily negative CAPS score, in which case I may really buy the stock. 18 seems like a good threshold for that move at the moment.

very promising MS drug Fampridine that helps MS patients walk better. NDA filed on Jan, 09, expected to be approved by end of 2009. Another good trait is that it is in form of oral pills.

Underperform

topped out

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

luv2b ;)!

biomedical firm promisses long term result

Big jump is too big. I'll watch it come down

Good stock to have right now.

This stock has been stuck into a classic pattern for the year. We're heading back into the upper $20's this summer. A recession at home isn't going to scare anyone into selling this gem.

Once they get Phamberine XR approved by the FDA the stock will shine, if not... well it's pretty much the end, they can't stay afloat with zanflax especially with all the debt they are using for research into XR.